Global Pneumococcal Vaccines Market 2014-2018

世界の肺炎球菌ワクチン市場(2014-2018)

◆タイトル:Global Pneumococcal Vaccines Market 2014-2018
◆商品コード:IRTNTR4125
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年9月10日
◆ページ数:64
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥316,400見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"世界の肺炎球菌ワクチン市場(2014-2018)"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、製品別分析、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About Pneumococcal Disease and Its Prevention
Pneumococcus (Streptococcus pneumonia), a pathogenic bacterium, is the leading cause of serious illness across the globe. It is the main cause of pneumonia, sinusitis, blood infections, meningitis, and middle ear infections (otitis media). Pneumococcal disease affects children and the elderly, and it is one of the leading infectious diseases worldwide. It kills almost 1.6 million people (including more than 800,000 children under the age five years) every year. Pneumococcal disease can be prevented by vaccination. Vaccination involves the introduction of dead or weakened antigen into the human body, which in turn produces lymphocytes to counter the infection and any future invasions by that antigen.

TechNavio’s analysts forecast the Global Pneumococcal Vaccines market to grow at a CAGR of 4.90 percent over the period 2013-2018.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Pneumococcal Vaccines market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of various vaccines administered to actively immunize pneumococcal disease caused by different serogroups of Streptococcus pneumonia.

TechNavio’s report, the Global Pneumococcal Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Pneumococcal Vaccines market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA

Key Vendors
• GlaxoSmithKline
• Merck
• Pfizer

Other Prominent Vendors
• Lupin
• Sanofi Pasteur MSD
• S K Chemicals

Market Driver
• Included Vaccine in National Immunization Schedule
• For a full, detailed list, view our report

Market Challenge
• Inadequate Coverage of Vaccine
• For a full, detailed list, view our report

Market Trend
• Increase in Strategic Alliances
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Product Type
07.1 Polysaccharide Vaccines
07.2 Conjugate Vaccines
08. Market Assessment of Top Pneumococcal Vaccines
08.1 Synflorix
08.2 Pneumovax 23
08.3 Prevnar
09. Geographical Segmentation
09.1 Pneumococcal Vaccines Market in the US 2013-2018
09.1.1 Market Size and Forecast
10. Rate of Incidence and Prevalence
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 GlaxoSmithKline
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation
19.1.4 Business Segmentation by Revenue 2012 and 2013
19.1.5 Sales by Geography
19.1.6 Pipeline Products
19.1.7 Business Strategy
19.1.8 Key Information
19.1.9 SWOT Analysis
19.2 Merck
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation by Revenue 2013
19.2.4 Business Segmentation by Revenue 2012 and 2013
19.2.5 Sales by Geography
19.2.6 Business Strategy
19.2.7 Key Developments
19.2.8 SWOT Analysis
19.3 Pfizer
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Revenue by Business Segmentation
19.3.5 Revenue Comparison 2012 and 2013
19.3.6 Sales by Geography
19.3.7 Business Strategy
19.3.8 Key Developments
19.3.9 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Pneumococcal Vaccines Market 2013-2018 (US$ million)
Exhibit 3: Global Pneumococcal Vaccines Market Segmentation by Product Type
Exhibit 4: Global Pneumococcal Vaccines Market Segmentation by Product Type 2013
Exhibit 5: Sales Comparison of Synflorix 2009-2013 (US$ million)
Exhibit 6: Region-wise Sales Comparison of Synflorix 2009-2013 (US$ million)
Exhibit 7: Sales Comparison of Synflorix in Europe 2009-2013 (US$ million)
Exhibit 8: Sales Comparison of Synflorix in EMAP 2010-2013 (US$ million)
Exhibit 9: Sales Comparison of Synflorix in ROW 2009-2013 (US$ million)
Exhibit 10: Global Sales Comparison of Pneumovax 2007-2013 (US$ milion)
Exhibit 11: Sales Comparison of Prevnar Family 2009-2013 (US$ million)
Exhibit 12: Sales Forecast of Prevnar 13 2014-2020 (in US$ billion)
Exhibit 13: Sales Comparison of Prevnar Family 2009-2013 (US$ million)
Exhibit 14: Global Pneumococcal Vaccines Market by Geographical Segmentation 2013
Exhibit 15: Pneumococcal Vaccines Market in the US 2013-2018 (US$ million)
Exhibit 16: Incidence of Childhood Clinical Pneumonia 2008
Exhibit 17: Global Pneumococcal Vaccines Market Share Analysis 2013
Exhibit 18: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 19: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 20: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 21: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 22: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 23: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 24: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 25: Pfizer Inc.: Business Segmentation
Exhibit 26: Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 27: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 28: Pfizer Inc.: Revenue by Geography 2013



【掲載企業】

GlaxoSmithKline,Merck ,Pfizer,Lupin,Sanofi Pasteur MSD,S K Chemicals

【資料のキーワード】

肺炎球菌ワクチン、肺炎レンサ球菌ワクチン、製薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[世界の肺炎球菌ワクチン市場(2014-2018)]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆